Literature DB >> 26521865

Literature review of visual representation of the results of benefit-risk assessments of medicinal products.

Christine E Hallgreen1, Shahrul Mt-Isa1, Alfons Lieftucht2, Lawrence D Phillips3, Diana Hughes4, Susan Talbot5, Alex Asiimwe6, Gerald Downey5, Georgy Genov7, Richard Hermann8, Rebecca Noel9, Ruth Peters1, Alain Micaleff10, Ioanna Tzoulaki1, Deborah Ashby1.   

Abstract

BACKGROUND: The PROTECT Benefit-Risk group is dedicated to research in methods for continuous benefit-risk monitoring of medicines, including the presentation of the results, with a particular emphasis on graphical methods.
METHODS: A comprehensive review was performed to identify visuals used for medical risk and benefit-risk communication. The identified visual displays were grouped into visual types, and each visual type was appraised based on five criteria: intended audience, intended message, knowledge required to understand the visual, unintentional messages that may be derived from the visual and missing information that may be needed to understand the visual.
RESULTS: Sixty-six examples of visual formats were identified from the literature and classified into 14 visual types. We found that there is not one single visual format that is consistently superior to others for the communication of benefit-risk information. In addition, we found that most of the drawbacks found in the visual formats could be considered general to visual communication, although some appear more relevant to specific formats and should be considered when creating visuals for different audiences depending on the exact message to be communicated.
CONCLUSION: We have arrived at recommendations for the use of visual displays for benefit-risk communication. The recommendation refers to the creation of visuals. We outline four criteria to determine audience-visual compatibility and consider these to be a key task in creating any visual. Next we propose specific visual formats of interest, to be explored further for their ability to address nine different types of benefit-risk analysis information.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  benefit-risk; communication; decision-making; medicines; pharmacoepidemiology; review; visual representation

Mesh:

Year:  2015        PMID: 26521865     DOI: 10.1002/pds.3880

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

1.  Using the Short Graph Literacy Scale to Predict Precursors of Health Behavior Change.

Authors:  Yasmina Okan; Eva Janssen; Mirta Galesic; Erika A Waters
Journal:  Med Decis Making       Date:  2019-03-08       Impact factor: 2.583

2.  Advancing regulatory science, advancing regulatory practice.

Authors:  Xavier Kurz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-02-21       Impact factor: 2.890

3.  Performance feedback on the quality of care in hospitals performing thrombectomy for ischemic stroke (PERFEQTOS): protocol of a stepped wedge cluster randomized trial.

Authors:  Marzyeh Amini; Sanne J den Hartog; Nikki van Leeuwen; Frank Eijkenaar; Laurien S Kuhrij; Lotte J Stolze; Paul J Nederkoorn; Hester F Lingsma; Adriaan C G M van Es; Ido R van den Wijngaard; Aad van der Lugt; Diederik W J Dippel; Bob Roozenbeek
Journal:  Trials       Date:  2021-12-04       Impact factor: 2.279

4.  Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).

Authors:  Hugo Arlegui; Kaatje Bollaerts; Vincent Bauchau; Gaëlle Nachbaur; Bernard Bégaud; Nicolas Praet
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

Review 5.  Improving Patient Preference Elicitation by Applying Concepts From the Consumer Research Field: Narrative Literature Review.

Authors:  Niki Ver Donck; Geert Vander Stichele; Isabelle Huys
Journal:  Interact J Med Res       Date:  2020-03-31

Review 6.  Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.

Authors:  Hugo Arlegui; Kaatje Bollaerts; Francesco Salvo; Vincent Bauchau; Gaëlle Nachbaur; Bernard Bégaud; Nicolas Praet
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.